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Abstract 
Eribulin mesylate has efficacy in patients who have received ≥2 prior chemotherapies for metastatic breast can-
cer (MBC) including an anthracycline and taxane. Phase 2 trials showed clinical activity and acceptable tolerability 
of first-line eribulin (HER2− MBC; Study 206) and eribulin plus trastuzumab (HER2+ MBC; Study 208). Prespecified 
analyses evaluated efficacy by prior anthracycline and/or taxane use. Patients received eribulin mesylate (1.4 mg/m2 
IV; Days 1 and 8) and, in Study 208, trastuzumab (8 mg/kg IV/Cycle 1, then 6 mg/kg; Day 1) in 21-day cycles. End-
points included objective response rate (ORR), progression-free survival (PFS), and tolerability. In Study 206 (N = 56), 
48 % of patients had received prior anthracycline, 46 % prior taxane, 36 % prior anthracycline and taxane, and 41 % 
were chemotherapy-naïve. In Study 208 (N = 52), these percentages were 21, 44, 17, and 52 %, respectively. In Study 
206, ORR and median PFS were similar for anthracycline-pretreated (25.9 %, 5.8 months), taxane-pretreated (26.9 %, 
5.8 months), anthracycline- and taxane-pretreated (25.0 %, 6.7 months), and anthracycline/taxane-naïve patients 
(30.4 %, 7.6 months). In Study 208, ORR/median PFS were 63.6 %/6.7 months among anthracycline-pretreated 
patients, 56.5 %/6.8 months among taxane-pretreated patients, 55.6 %/5.9 months among anthracycline- and taxane-
pretreated patients, and 81.5 %/13.1 months among anthracycline/taxane-naïve patients. Tolerability was generally 
similar among subgroups. In these studies, first-line eribulin in HER2− MBC and eribulin/trastuzumab in HER2+ MBC 
was effective with acceptable tolerability, regardless of prior anthracycline/taxane treatment. Prior chemotherapy 
was associated with lower ORR and shorter PFS with eribulin/trastuzumab in HER2+ MBC but not with eribulin in 
HER2− MBC.
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Background
In the US, approximately 5–10  % of women diagnosed 
with breast cancer (BC) have de novo metastatic dis-
ease and have an estimated 5-year survival rate of 24.3 % 
(National Cancer Institute 2014; American Cancer Soci-
ety 2014). In addition, approximately 30  % of patients 
with stage I to III BC at diagnosis will subsequently 
develop metastatic disease (O’Shaughnessy 2005). Treat-
ment selection for metastatic breast cancer (MBC) is 
guided by several factors, including patients’ choices, 
hormone receptor (estrogen receptor and progesterone 
receptor) expression, human epidermal growth factor 
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receptor 2 (HER2) expression, site and burden of metas-
tases, disease-related symptoms, prior treatment history, 
toxicity, comorbid conditions, patient age, and meno-
pausal status, amongst others (National Comprehensive 
Cancer Network 2015; Partridge et al. 2014).
The overall rate of BC that overexpresses the trans-
membrane tyrosine kinase receptor, HER2, is 22.2  % as 
was demonstrated in a recent survey of 107 published 
studies involving 39,730 patients (Ross et  al. 2009). Pre-
ferred single agents for MBC chemotherapy according 
to NCCN guidelines include anthracyclines, taxanes, 
antimetabolites (e.g., capecitabine and gemcitabine), and 
other microtubule disrupting agents (e.g., vinorelbine 
and eribulin) (National Comprehensive Cancer Network 
2015). Current guidelines recommend sequential single-
agent chemotherapy (in most cases) for HER2-negative 
(HER2−) MBC that is hormone receptor-negative or 
endocrine-resistant; however, there is not a single specific 
preferred chemotherapy agent or regimen (National Com-
prehensive Cancer Network 2015; Partridge et  al. 2014). 
For women with HER2-positive (HER2+) metastatic 
disease, trastuzumab, a humanized monoclonal anti-
body directed against the extracellular domain of HER2 
(Valabrega et al. 2007), combined with recently approved 
pertuzumab and a taxane (docetaxel or paclitaxel) are rec-
ommended as first-line therapy (National Comprehensive 
Cancer Network 2015; Giordano et al. 2014).
Eribulin is a non-taxane microtubule inhibitor that is 
a structurally modified synthetic analog of halichondrin 
B (Jordan et al. 2005; Okouneva et al. 2008; Smith et al. 
2010; Jordan and Kamath 2007). Eribulin has a unique 
mode of cytotoxic action that is distinct from those of 
other tubulin-targeting agents; it binds and inhibits only 
the growing +  ends, inhibiting the microtubule growth 
phase without affecting the shortening phase and causes 
tubulin sequestration into non-productive aggregates. 
This novel tubulin-directed mechanism may explain 
eribulin’s observed non-cross-resistant antitumor activity 
following taxane therapy (Jordan et  al. 2005; Okouneva 
et  al. 2008; Smith et  al. 2010; Jordan and Kamath 2007; 
Jain and Cigler 2012).
In women with MBC who had previously received at 
least 2 chemotherapeutic regimens (including an anthra-
cycline and a taxane) for metastatic disease, eribulin has 
demonstrated antitumor activity and improved over-
all survival (Vahdat et  al. 2009; Cortes et  al. 2010; Aogi 
et al. 2012; Cortes et al. 2011; Halaven® 2014). Approval 
by the United States (US) Food and Drug Administration 
for eribulin in this setting was based on the results from 
the phase 3 EMBRACE study, where single-agent eribulin 
significantly improved overall survival (OS) in patients 
with MBC compared with treatment of physician’s choice 
(Cortes et al. 2011). A more recent phase 3 study, which 
compared eribulin and capecitabine as first-, second-, or 
third-line therapy for MBC in women who had previ-
ously received an anthracycline and a taxane, found no 
significant difference in OS between the 2 treatments 
[hazard ratio 0.88 (95 % CI 0.77, 1.00); p = 0.056]; how-
ever, for eribulin the median OS (15.9 months), median 
PFS (4.1  months), and objective response rate (11  %) 
were comparable to those achieved with eribulin in the 
EMBRACE trial (13.1, 3.7  months, and 12  %, respec-
tively) (Cortes et al. 2011; Kaufman et al. 2015).
Due to its antitumor activity in the challenging set-
ting of late-line treatment, infusion schedule (1.4 mg/m2 
IV over 2–5 min on Days 1 and 8 of a 21-day cycle), and 
lack of premedication requirement to prevent hypersen-
sitivity, assessment of eribulin in the first-line setting for 
women with MBC was of clinical interest (Cortes et  al. 
2011; Halaven® 2014). Results from two, single-arm, mul-
ticenter, phase 2 trials, Study 206 (eribulin monotherapy 
in HER2−  MBC) and Study 208 (combination eribulin 
plus trastuzumab in HER2+  MBC), as first-line treat-
ment in patients with locally recurrent BC or MBC have 
been published (McIntyre et al. 2014; Wilks et al. 2014). 
In Study 206 (N = 56), the objective response rate (ORR) 
with single-agent eribulin was 29 %, median duration of 
response (DOR) was 5.8  months, and median progres-
sion-free survival (PFS) was 6.8 months (McIntyre et al. 
2014). In Study 208 (N = 52), ORR with eribulin/trastu-
zumab was 71.2  %, median DOR was 11.1  months, and 
median PFS was 11.6 months (Wilks et al. 2014). Because 
many patients receive an anthracycline as adjuvant or 
neoadjuvant (neo/adjuvant therapy), we conducted a 
prespecified analysis of both trials to examine efficacy of 




Complete trial methodology for the 206 and 208 stud-
ies have been previously published (McIntyre et  al. 
2014; Wilks et al. 2014). Both were multicenter, phase 2, 
open-label trials that assessed eribulin as first-line treat-
ment in patients with HER2−  locally recurrent BC or 
MBC not previously treated with chemotherapy in the 
metastatic setting (Study 206) or eribulin combined with 
trastuzumab treatment in patients with HER2+  locally 
recurrent BC or MBC (Study 208). Both studies were 
conducted in accordance with the Declaration of Hel-
sinki, and the protocols and informed consent forms were 
approved by institutional review boards. All patients for 
both studies provided written informed consent before 
undergoing any study-related procedures.
Page 3 of 10O’Shaughnessy et al. SpringerPlus  (2015) 4:532 
Endpoints
Prespecified analyses included evaluation of the primary 
and secondary endpoints of ORR and PFS, respectively, 
according to prior neo/adjuvant anthracycline or taxane 
pretreatment. For both trials, the primary efficacy vari-
able was ORR, defined as the proportion of patients who 
achieved an overall best response of complete response 
(CR) or a partial response (PR). PFS was measured from 
the start of treatment until disease progression or death 
from any cause. The censoring rules for PFS were accord-
ing to FDA guidance in 2007. Tumor assessments were 
performed every 6 weeks in the first 6 cycles and every 
12 weeks thereafter using RECIST v1.1.
Safety/tolerability
Safety evaluations at baseline and subsequent visits 
included adverse events (AEs), clinical laboratory tests, 
physical examination, vital signs, and electrocardiogram 
assessments. Treatment-emergent AEs (TEAEs) were 
defined as AEs that started or worsened after the first 
dose of study treatment.
Statistical analysis
The statistical methods have been published with the pri-
mary analyses for Studies 206 and 208 (McIntyre et  al. 
2014; Wilks et al. 2014). Efficacy analyses were based pri-
marily on the full analysis set (FAS), which included all 
patients who received ≥1 dose(s) of study treatment. The 
safety analysis set included all patients who received ≥1 
dose(s) of eribulin and had ≥1 postbaseline safety evalu-
ation. All efficacy endpoints were summarized descrip-
tively. Kaplan–Meier method was used to estimate the 
time to event variables (e.g., PFS). Greenwood method 
was used to construct 95 % confidence interval (95 % CI) 
for the median. Exact method was used to construct 95 % 
CI for rate variables (e.g., ORR). Statistical analyses and 




In Study 206 (single-agent eribulin in HER2− MBC), 56 
female patients were enrolled, of which, 48  % (n =  27) 
had received prior anthracycline treatment and 46  % 
(n  =  26) had received prior taxane treatment, 36  % 
(n  =  20) had received both anthracycline and taxane, 
and 41  % (n  =  23) were anthracycline- and taxane-
naïve (Table  1). For Study 206 patients, mean age was 
57.0  years. Median relative delivered dose intensity for 
eribulin treatment ranged from 98.7 to 98.9  % across 
the anthracycline- and/or taxane-pretreated sub-
groups. Median treatment duration was 19.1  weeks 
in anthracycline-pretreated patients, 16.1  weeks in 
taxane-pretreated patients, 21.4 weeks in anthracycline- 
and taxane-pretreated patients, and 27.0  weeks anthra-
cycline- and taxane-naïve patients.
Fifty-two patients were enrolled in Study 208 (eribu-
lin plus trastuzumab in HER2+  MBC), of which, 21  % 
(n  =  11) had received prior anthracycline treatment, 
44  % (n  =  23) prior taxane treatment, 17  % (n  =  9) 
had received both anthracycline and taxane, and 52  % 
(n = 27) were anthracycline- and taxane-naïve (Table 2). 
Mean age was 58.7  years and median delivered rela-
tive dose intensity for eribulin treatment across all 
anthracycline- and taxane-pretreatment subgroups 
ranged from 93.8 to 98.5 %. Median treatment duration 
was 28.0  weeks in anthracycline-pretreated patients, 
28.1  weeks in taxane-pretreated patients, 21.4  weeks 
in anthracycline- and taxane-pretreated patients, and 
37.3 weeks in anthracycline- and taxane-naïve patients.
Data regarding eribulin administration for Studies 206 
and 208 including duration, relative dose intensity, and 
average treatment day dose can found in Additional file 1: 
Table S1.
Efficacy outcomes
In Study 206, ORR and median PFS were 25.9  % and 
5.8  months among patients who had received prior 
anthracycline, 26.9  % and 5.8  months among patients 
who had received prior taxane, 25.0  % and 6.7  months 
among patients who had received both anthracycline and 
taxane, and 30.4 % and 7.6 months among patients who 
were anthracycline- and taxane-naïve (Table 3; Fig. 1a).
In Study 208, ORR and median PFS were 63.6  % and 
6.7  months among anthracycline-pretreated patients, 
56.5 % and 6.8 months among taxane-pretreated patients, 
55.6  % and 5.9  months among anthracycline- and tax-
ane-pretreated patients, and 81.5  % and 13.1  months 
among anthracycline- and taxane-naïve patients (Table 3; 
Fig. 1b).
Safety/tolerability
In Study 206, rates of serious TEAEs were similar in 
patients who had received prior anthracycline (29.6  %) 
and in those who had received prior taxane treatment 
(26.9 %); rates were 20.0 % in patients who had received 
both anthracycline and taxane, and 26.1  % in patients 
who were anthracycline- and taxane-naive. In Study 208, 
rates of serious TEAEs were 27.3 % in patients who had 
received prior anthracycline, 30.4 % in patients who had 
received prior taxane treatment, 33.3 % in patients who 
had received both anthracycline and taxane, and 29.6 % 
in patients who were anthracycline- and taxane-naive.
In Study 206, dose modifications due to AEs occurred 
at a similar rate in patients who had received prior 
anthracycline (66.7  %), prior taxane (65.4  %), or both 
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Table 1 Study 206 (Single-Agent Eribulin in HER2− MBC): demographics and baseline characteristics
SD standard deviation
With prior anthracycline 
(n = 27)
With prior taxane  
(n = 26)
With prior anthracycline 
and taxane (n = 20)
Without prior anthracycline 
or taxane (n = 23)
Female, n (%) 27 (100) 26 (100) 20 (100) 23 (100)
Age (years)
 Mean (SD) 55 (10) 55 (11) 55 (11) 61 (11)
Age group, n (%)
 <50 years 9 (33) 9 (35) 7 (35) 3 (13)
 50–65 years 13 (48) 11 (42) 8 (40) 10 (43)
 >65 years 5 (19) 6 (23) 5 (25) 10 (43)
Age at diagnosis (years)
 Mean (SD) 49 (10) 52 (11) 52 (10) 57 (11)
Estrogen receptor (ER) status, n (%)
 + 17 (63) 13 (50) 11 (55) 22 (96)
 – 10 (37) 13 (50) 9 (45) 1 (4)
Progesterone receptor (PR) status, n (%)
 + 18 (67) 13 (50) 12 (60) 19 (83)
 – 9 (33) 13 (50) 8 (40) 4 (17)
HER2 status, n (%)
 + 0 0 0 0
 – 27 (100) 26 (100) 20 (100) 23 (100)
Table 2 Study 208 (Eribulin + Trastuzumab in HER2+ MBC): demographics and baseline characteristics
SD standard deviation
With prior anthracycline  
(n = 11)
With prior taxane  
(n = 23)
With prior anthracycline 
and taxane (n = 9)
Without prior anthracycline 
or taxane (n = 27)
Sex, n (%)
 Female 11 (100) 23 (100) 9 (100) 26 (96)
 Male 0 0 0 1 (4)
Age (years)
 Mean (SD) 57 (12) 60 (11) 58 (12) 58 (11)
Age group, n (%)
 <50 years 4 (36) 5 (22) 3 (33) 5 (19)
 50–65 years 3 (27) 8 (35) 2 (22) 15 (56)
 ≥65 years 4 (36) 10 (43) 4 (44) 7 (26)
Age at diagnosis (years)
 Mean (SD) 51 (14) 56 (12) 54 (14) 58 (11)
Estrogen receptor (ER) status
 + 7 (64) 14 (61) 6 (67) 20 (74)
 – 3 (27) 9 (39) 3 (33) 7 (26)
 Not done 1 (9) 0 0 0
Progesterone receptor (PR) status
 + 5 (45) 10 (43) 4 (44) 11 (41)
 – 5 (45) 13 (57) 5 (56) 16 (59)
 Not done 1 (9) 0 0 0
HER2 status, n (%)
 + 11 (100) 23 (100) 9 (100) 27 (100)
 – 0 0 0 0
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anthracycline and taxane (70.0  %), but the rate was 
lower among patients who were anthracycline- and 
taxane-naïve (43.5  %). In Study 208, dose modifications 
occurred at a similar rate in patients who had received 
prior anthracycline (54.5  %), prior taxane (56.5  %), or 
both anthracycline and taxane (55.6 %), and were slightly 
higher in patients who were anthracycline- and taxane-
naïve (63.0 %).
Rates of peripheral neuropathy and neutropenia are 
summarized in Table  4. In Study 206, rates of grade 2 
(15.4–20.0 %) and grade 3 neuropathy (18.5–26.1 %) were 
generally similar, regardless of prior treatment (no grade 
≥4 neuropathy was reported). The rate of neutropenia 
was lower among patients who were anthracycline- and 
taxane-naive (56.5  %), and was relatively similar among 
the other three groups (77.8–84.6  %). In Study 208, 
patients who had received taxanes had higher rates of 
grade 2 neuropathy (30.4 %) relative to the other groups 
(14.8–22.2 %), while those who were anthracycline- and 
taxane-naive had higher rates of grade 3 neuropathy 
(37.0  %) relative to the other groups (11.1–18.2  %); no 
grade ≥4 neuropathy was reported. The rate of neutro-
penia was higher among those who had received prior 
anthracyclines (81.8 %) and those who had received both 
prior anthracycline and taxane (77.8 %), somewhat lower 
among those who had received prior taxane (65.2 %), and 
lowest among those who were anthracycline- and taxane- 
naïve (51.9 %).
Discussion
First-line therapy for recurrent BC or MBC with eribu-
lin (Study 206) or eribulin plus trastuzumab (Study 208) 
demonstrated antitumor activity with acceptable toler-
ability irrespective of prior anthracycline and/or taxane 
treatment. For Study 206, ORR was similar regardless of 
prior anthracycline and/or taxane treatment (ORR range: 
25.0–30.4  %), although median PFS was slightly longer 
among patients who were both anthracycline- and tax-
ane-naïve (7.6 months) relative to those who had received 
prior treatment (range 5.8–6.7  months). In Study 208, 
ORR was higher (81.5 %) and median PFS (13.1 months) 
was longer in patients who had not received prior anthra-
cycline or taxane treatment compared to those who had 
received prior anthracycline and/or taxane treatment 
(ORR range 55.6–63.6  %; PFS range 5.9–6.8  months), 
suggesting that patients who are both anthracycline- and 
taxane-naïve have prolonged benefit from first-line eribu-
lin plus trastuzumab.
Results for Study 206 presented here are comparable to 
those obtained with single-agent anthracyclines or taxa-
nes. In a phase 3 study that compared doxorubicin and 
pegylated liposomal doxorubicin (N = 509), ORRs were 
38 and 33 %, respectively, with 25 % of patients in each 
group having stable disease (SD), and a PFS of 7.8 and 
6.9 months, respectively (O’Brien et al. 2004). In an anal-
ysis of individual patient data from studies using first-
line single-agent anthracycline (doxorubicin) or taxane 
therapy (paclitaxel or docetaxel), ORRs were 38  % with 
anthracyclines and 33 % for taxanes (P =  0.08), and SD 
of 37 and 40 %, with a median PFS of 7.2 and 5.1 months, 
respectively (Piccart-Gebhart et al. 2008).
In Study 208, eribulin plus trastuzumab as first-line 
treatment for patients with HER2+  locally advanced BC 


































































































Fig. 1 a Study 206 (Single-Agent Eribulin): Kaplan–Meier plot of progression-free survival by prior anthracycline (A) and/or taxane (T) treatment. b 
Study 208 (Eribulin + Trastuzumab): Kaplan–Meier plot of progression-free survival by prior anthracycline (A) and/or taxane (T) treatment
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those reported for other chemotherapy combinations eval-
uated in this setting. Studies of trastuzumab plus docetaxel 
demonstrated ORRs ranging from 45 to 61  % and PFS 
ranging from 8.3 to 12.4 months (Hurvitz et al. 2013; Ser-
vitja et al. 2012; Andersson et al. 2011; Marty et al. 2005). A 
study that compared vinorelbine plus trastuzumab vs doc-
etaxel plus trastuzumab reported an ORR of 59.3 % in both 
arms and time to progression of 15.3 and 12.4  months, 
respectively (Andersson et al. 2011). A study of combined 
oral or IV vinorelbine with trastuzumab reported an ORR 
of 70.3 % and time to progression of 9.3 months (Heine-
mann et  al. 2011). The combination of capecitabine plus 
trastuzumab has resulted in an ORR of 38–65 % and PFS 
of 7.8  months (Yamamoto et  al. 2008; Michalaki et  al. 
2010). ORRs from 36 to 75  % and PFS ranging from 7.1 
to 9.9  months were demonstrated in trials combining 
trastuzumab and paclitaxel (Fountzilas et  al. 2001; Gas-
parini et  al. 2007; Robert et  al. 2006). For the combina-
tion of trastuzumab plus paclitaxel and carboplatin, a PFS 
of 10.7 months and an ORR of 52 % was reported (Rob-
ert et  al. 2006). However, with the large improvement in 
median OS observed with the addition of pertuzumab 
to docetaxel and trastuzumab as first-line treatment for 
HER2+ MBC (Baselga et al. 2012; Swain et al. 2013, 2014), 
the combination of trastuzumab plus pertuzumab and 
docetaxel (or paclitaxel) is recommended as the preferred 
standard of care (National Comprehensive Cancer Net-
work 2015). The NCCN guidelines include trastuzumab 
alone or with docetaxel, vinorelbine, capecitabine, or 
paclitaxel; with or without carboplatin, as other first-line 
options (National Comprehensive Cancer Network 2015).
In both studies, tolerability was generally similar for 
chemotherapy-naïve patients and patients who had 
received prior anthracyclines and/or taxanes. In Study 
206, the rate of serious TEAEs among chemotherapy-
naïve patients was similar to the rates among anthracy-
cline-pretreated patients and taxane-pretreated patients, 
although the rate was lower among patients who had 
received both anthracycline and taxane treatment. In 
Study 208, rates of serious TEAEs were comparable for 
chemotherapy-naïve and patients with prior anthra-
cycline and/or taxane treatment. In both studies, rates 
of neuropathy (any grade) were similar among the sub-
groups of patients who had received prior anthracycline 
and/or taxane treatment; the rate among chemotherapy-
naïve patients was greater than the rate among pretreated 
patients in Study 206 and was comparable to the rate 
among pretreated patients in Study 208. In both studies, 
rates of grade 2 and 3 neuropathy (no grade ≥4 neuropa-
thy was reported) among patients who had received prior 
taxane treatment were comparable to or less than the 
rates among chemotherapy-naïve patients.
Conclusions
As first-line therapy, eribulin in patients with HER2−
MBC and eribulin plus trastuzumab in patients with 
HER2+  MBC was effective with acceptable toler-
ability, regardless of prior anthracycline or taxane 
treatment. In Study 206 (patients with HER2−  MBC 
receiving eribulin only), ORRs and median PFS dura-
tion were similar in patients who had received prior 
anthracycline treatment and/or prior taxane therapy, 
although patients who were both anthracycline- and 
taxane-naïve had slightly longer median PFS. For 
Study 208 (patients with HER2+ MBC receiving com-
bination eribulin/trastuzumab), ORR was higher and 
median PFS was longer among anthracycline- and 
taxane-naïve patients treated with eribulin plus tras-
tuzumab compared with patients who had received 
prior anthracycline and/or taxane treatment. These 
data demonstrated that eribulin is an active agent in 
chemotherapy-naïve as well as in anthracycline- and/or 
taxane-pretreated patients with MBC.
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